Dr. Joshua Arbesman is a physician-scientist in the Departments of Dermatology and Cancer Biology at Cleveland Clinic. He specializes in caring for patients with a history of melanoma and a high risk for skin cancer development. He co-leads the Gross Family Melanoma Registry and conducts research to better understand inherited predisposition to melanoma.
“Genetic testing for mutations in CDKN2A skin cancer gene through organizations like JScreen is highly recommended. A person with a hereditary risk of familial malignant melanoma has a greatly increased risk of developing melanoma during their lifetime. Genetic testing can determine that, and there are many precautions that can be taken before signs of melanoma begin to appear.”